EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies

Chen Yu, Chanyuan Wu, Shangyi Jin, Liying Peng, Xinwang Duan, Pinting Yang, Wei Wei, Yanhong Wang, Mucong Li, Shuang Zhou, Shengyun Liu, Jing Wang und 11 weitere

Journal of the American Academy of Dermatology · 2025-12 · 93 (6) · 1422-1431

DOI: 10.1016/j.jaad.2025.06.062 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2025-12. Verfasst von Chen Yu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical …. Hauptthemen laut MEDLINE: Myositis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune diseases with variable long-term outcomes. OBJECTIVE: To determine the prognosis of IIM. METHODS: This multicenter, prospective cohort study included Chinese patients with IIM. We calculated the standardized mortality ratios adjusted for age and sex, analyzed causes of death, and identified risk factors for all-cause mortality using a multivariable Cox proportional hazards model. RESULTS: A total of 4534 patients were included, with 2902 dermatomyositis, 592 polymyositis, 927 anti-synthetase syndrome, and 113 immune-mediated necrotizing myopathy. Five hundred ten patients died with a median follow-up time of 46 months. The overall standardized mortality ratio was 6.2 (95% CI: 5.7-6.7). Cumulative survival rates at 1, 3, and 10 years were 92.6%, 88.6%, and 80.5%, respectively. Leading causes of death included interstitial lung diseases (18.8%), malignancies (18.8%), cardiovascular diseases (18.8%), and infections (18.6%), which shifted over time (from interstitial lung disease/infection to malignancies/cardiovascular diseases). Risk factors for mortality included male, lymphopenia, high serum ferritin, anti-melanoma differentiation-associated gene 5, anti-transcription intermediary factor 1 gamma (anti-TIF1γ), and anti-Ro 52 antibodies. LIMITATIONS: Underestimation of anti-synthetase syndrome and immune-mediated necrotizing myositis. CONCLUSION: IIM patients had significantly higher mortality than the general population, with variable causes of death and distinct risks based on myositis-specific antibodies. Myositis-associated autoantibodies-based classification may provide deeper insights into pathogenesis and management of IIM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyositisHumansMaleFemaleMiddle AgedProspective StudiesCause of DeathRegistriesAdultRisk FactorsAgedChinaPrognosisSurvival RateDermatomyositisTime FactorsProportional Hazards ModelsPolymyositis

Stichwörter der Autor:innen

anti-synthetase syndromecause of deathdermatomyositisidiopathic inflammatory myopathyimmune-mediated necrotizing myopathymortalitymyositis-specific autoantibodypolymyositisprognosisrisk factor

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immuno…
  • Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Rheumatology, The First Hospital of China Medical University, Shenyang, China.
  • Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Epidemiology and Bio-statistics (YW), Institute of Basic Medical Science, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Förderung

  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China
  • Peking Union Medical College Hospital

Zitieren

APA

Yu, C., Wu, C., Jin, S., Peng, L., Duan, X., Yang, P., Wei, W., Wang, Y., Li, M., Zhou, S., Liu, S., Wang, J., Li, H., Zheng, Z., Shi, X., Xu, J., Wang, Y., Zhao, J., Xu, D., …, & Wang, Q. (2025). The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies. Journal of the American Academy of Dermatology, 93(6), 1422-1431. https://doi.org/10.1016/j.jaad.2025.06.062

Vancouver

Yu C, Wu C, Jin S, Peng L, Duan X, Yang P, et al. The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies. Journal of the American Academy of Dermatology. 2025;93(6):1422-1431. doi:10.1016/j.jaad.2025.06.062

BibTeX
@article{Yu2025,
  author = {Yu, Chen and Wu, Chanyuan and Jin, Shangyi and Peng, Liying and Duan, Xinwang and Yang, Pinting and Wei, Wei and Wang, Yanhong and Li, Mucong and Zhou, Shuang and Liu, Shengyun and Wang, Jing and Li, Hongbin and Zheng, Zhaohui and Shi, Xiaofei and Xu, Jian and Wang, Yongfu and Zhao, Jiuliang and Xu, Dong and Yin, Peng and Zeng, Xiaofeng and Li, Mengtao and Wang, Qian},
  title = {The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  volume = {93},
  number = {6},
  pages = {1422--1431},
  doi = {10.1016/j.jaad.2025.06.062}
}
Kostenlos starten →